Foreword: hepatocellular carcinoma: emerging treatments, drug targets, and fundamental knowledge gaps

Alessandro Rizzo; Gennaro Palmiotti

doi:10.1080/13543784.2022.2046732

Foreword: hepatocellular carcinoma: emerging treatments, drug targets, and fundamental knowledge gaps

Expert Opin Investig Drugs. 2022 Apr;31(4):331. doi: 10.1080/13543784.2022.2046732. Epub 2022 Mar 2.

Authors

Alessandro Rizzo¹, Gennaro Palmiotti¹

Affiliation

¹ Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico "Don Tonino Bello," I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy.

PMID: 35196947
DOI: 10.1080/13543784.2022.2046732

No abstract available

Keywords: Atezolizumab; Bevacizumab; Camrelizumab; Durvalumab; Hepatocellular carcinoma; Immunotherapy; Lenvatinib; immunotherapy; pembrolizumab; transarterial chemoembolization.

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Carcinoma, Hepatocellular* / drug therapy
Drug Delivery Systems
Humans
Liver Neoplasms* / drug therapy

Substances

Antibodies, Monoclonal, Humanized